← Oncology Approval Tracker

FDA DECISION ·

Scemblix

asciminib · Novartis

Accelerated approvalNew or expanded indicationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.

LAMPGEN ANALYSIS

Why it matters

The allosteric BCR::ABL1 inhibitor moved into the newly diagnosed setting, with molecular response supporting accelerated approval.

What research teams should watch

Standardize BCR::ABL1 reporting on the International Scale and record test timing, adherence and treatment interruptions.

PRIMARY RECORDS

Sources